MedPath

Rilonacept

Generic Name
Rilonacept
Brand Names
Arcalyst, 炎朵
Drug Type
Biotech
CAS Number
501081-76-1
Unique Ingredient Identifier
8K80YB5GMG

Overview

Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.

Background

Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.

Indication

用于治疗成人及12岁青少年罕见病周期性综合征(CAPS),即家族性寒冷型自身炎症综合征和穆-韦(Muckle-Wells)两氏综合征。

Associated Conditions

  • Cryopyrin-associated Periodic Syndromes (CAPS)
  • Deficiency of the interleukin-1 receptor antagonist
  • Familial Cold Autoinflammatory Syndrome (FCAS)
  • Muckle-Wells Syndrome (MWS)
  • Recurrent Pericarditis

FDA Approved Products

Arcalyst
Manufacturer:Kiniksa Pharmaceuticals (UK), Ltd.
Route:SUBCUTANEOUS
Strength:160 mg in 2 mL
Approved: 2023/05/08
NDC:73604-914

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath